Title (en)

USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME IN PREPARATION OF DRUGS FOR TREATING ADVANCED SOLID TUMORS

Title (de)

VERWENDUNG VON MITOXANTRONHYDROCHLORIDLIPOSOMEN ZUR HERSTELLUNG VON ARZNEIMITTELN ZUR BEHANDLUNG FORTGESCHRITTENER SOLIDER TUMOREN

Title (fr)

UTILISATION DE LIPOSOME DE CHLORHYDRATE DE MITOXANTRONE DANS LA PRÉPARATION DE MÉDICAMENTS POUR LE TRAITEMENT DE TUMEURS SOLIDES AVANCÉES

Publication

EP 4349325 A1 20240410 (EN)

Application

EP 22810645 A 20220527

Priority

• CN 202110593815 A 20210528
• CN 2022095446 W 20220527

Abstract (en)

Disclosed is the use of a mitoxantrone hydrochloride liposome in the preparation of drugs for treating advanced solid tumors. A higher therapeutically effective amount of mitoxantrone hydrochloride liposome, for example 8-150 mg/m², is administered to patients with the advanced solid tumors. Animal test results show that the mitoxantrone hydrochloride liposome can effectively inhibit the growth of various solid tumor transplantation tumors. Clinical research results show that the mitoxantrone hydrochloride liposome can effectively treat advanced solid tumors, and is safe and controllable.

IPC 8 full level

A61K 9/127 (2006.01); A61K 31/136 (2006.01); A61P 35/00 (2006.01)

CPC (source: CN EP US)

A61K 9/0019 (2013.01 - CN EP US); A61K 9/127 (2013.01 - CN US); A61K 9/1271 (2013.01 - EP); A61K 31/136 (2013.01 - CN EP US); A61K 47/24 (2013.01 - CN); A61P 35/00 (2018.01 - CN EP US)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

EP 4349325 A1 20240410; CN 115400083 A 20221129; JP 2024519172 A 20240508; US 2024269092 A1 20240815; WO 2022247921 A1 20221201

DOCDB simple family (application)

EP 22810645 A 20220527; CN 2022095446 W 20220527; CN 202210594857 A 20220527; JP 2023573203 A 20220527; US 202218564796 A 20220527